[Vasopressin as a rescue vasopressor agent. Treatment of selected cardiogenic shock states].
Vasodilatory shock is the most common form of shock in the critically ill patient. As a consequence of overwhelming and prolonged mediator production, vasodilatory shock can be the common final pathway of primary non-vasodilatory shock (e.g. cardiogenic or hypovolemic shock). A supplementary infusion of arginine vasopressin (AVP) showed beneficial effects on hemodynamics and potentially on the outcome in patients with vasodilatory shock due to sepsis or after major surgery. In this case series, successful administration of AVP in three surgical patients with primary cardiogenic shock forms is reported. The hemodynamic effects of AVP were comparable to those AVP-induced alterations described in septic shock and seem to be predominantly mediated by potent vasoconstriction and the facilitated reduction of higher, potentially toxic catecholamine doses. Thus, an AVP-induced decrease in heart rate and pulmonary arterial pressures may be particularly beneficial in patients with impaired cardiac function.
Mayr
V D
VD
Klinik für Anästhesie und Allgemeine Intensivmedizin, Medizinische Universität Innsbruck, Innsbruck.
Luckner
G
G
Jochberger
S
S
Wenzel
V
V
Hasibeder
W R
WR
Dünser
M W
MW
D000368:Aged; D000369:Aged, 80 and over; D001127:Arginine Vasopressin / Q000627:therapeutic use*; D001794:Blood Pressure / Q000187:drug effects; D016638:Critical Illness; D003924:Diabetes Mellitus, Type 2 / Q000150:complications; D005260:Female; D006333:Heart Failure / Q000188:drug therapy; D006339:Heart Rate / Q000187:drug effects; D006801:Humans; D006949:Hyperlipidemias / Q000150:complications; D006973:Hypertension / Q000150:complications; D008297:Male; D008875:Middle Aged; D009203:Myocardial Infarction / Q000150:complications; D011183:Postoperative Complications / Q000188:drug therapy*; D011669:Pulmonary Wedge Pressure / Q000187:drug effects; D018805:Sepsis / Q000188:drug therapy; D012770:Shock, Cardiogenic / Q000188:drug therapy*; D016896:Treatment Outcome; D014662:Vasoconstrictor Agents / Q000627:therapeutic use*
D014662:Vasoconstrictor Agents; D001127:Arginine Vasopressin